Stathmin表达与局部晚期口腔鳞癌患者TPF诱导化疗远期疗效的相关性分析

doi:10.19438/j.cjoms.2021.03.006

中国口腔颌面外科杂志 ›› 2021, Vol. 19 ›› Issue (3): 217-221.doi: 10.19438/j.cjoms.2021.03.006

Stathmin表达与局部晚期口腔鳞癌患者TPF诱导化疗远期疗效的相关性分析

谈亦然¹, 赵铜超¹, 王丽珍², 李江², 琚梧桐^1,*, 朱东旺¹, 张志愿¹, 钟来平^1,*

1.上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,
2.口腔病理科,上海交通大学口腔医学院,国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2020-12-07 修回日期:2021-03-11 发布日期:2021-07-16
通讯作者: 琚梧桐,E-mail：juwutong@163.com;钟来平,E-mail：zhonglaiping@163.com。^*共同通信作者
作者简介:谈亦然（1988-）,男,硕士,医师,E-mail：gordon-tan@foxmail.com
基金资助:
国家自然科学基金（81972525、81672660）; 上海市卫生健康委员会学科带头人计划（2018BR41）; 上海交通大学医学院附属第九人民医院临床研究型MDT项目（201916）

Stathmin expression correlated with the long-term survival benefit from TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma

TAN Yi-ran¹, ZHAO Tong-chao¹, WANG Li-zhen², LI Jiang², JU Wu-tong¹, ZHU Dong-wang¹, ZHANG Zhi-yuan¹, ZHONG Lai-ping¹

1. Department of Oromaxillofacial Head and Neck Oncology,
2. Department of Oral Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2020-12-07 Revised:2021-03-11 Published:2021-07-16

摘要/Abstract

摘要： 目的验证微管解聚蛋白（Stathmin）能否预测口腔鳞癌（oral squamous cell carcinoma,OSCC）患者从多西紫杉醇、顺铂、5氟尿嘧啶（TPF）诱导化疗中远期获益。方法收集2008年3月—2010年12月入组TPF诱导化疗临床试验的256例OSCC患者的远期随访结果。收集患者肿瘤活检标本,进行Stathmin免疫组织化学染色并评分。根据Stathmin表达评分进行亚组预后分析。采用SPSS 13.0软件包将Stathmin和其他基线特征进行单因素、多因素和Cox回归模型预后分析。结果 Stathmin的表达可预测OSCC患者对TPF诱导化疗的反应,Stathmin低表达的OSCC患者从TPF诱导化疗中获益,而高Stathmin表达的OSCC患者不能获益于TPF诱导化疗。Stathmin的表达是独立的预测因子。结论 Stathmin是独立的预测OSCC诱导化疗疗效的生物标志物,基于Stathmin筛选指导OSCC患者接受TPF诱导化疗的后续临床研究具有重要意义。

关键词: 口腔鳞癌, 微管解聚蛋白, 诱导化疗, 预后

Abstract: PURPOSE: This study analyzed the role of Stathmin as a predictive biomarker on the long-term benefit of TPF induction chemotherapy based on a 11-year follow-up results. METHODS: Long-term follow-up results of 256 oral squamous cell carcinoma (OSCC) patients enrolled in the TPF induction chemotherapy trial were collected. Tumor biopsy specimens were collected for Stathmin immunohistochemical staining and scoring. Subgroup prognosis was analyzed according to the Stathmin expression. Stathmin and other baseline characteristics were analyzed by univariate, multivariate, and Cox regression model with SPSS 13.0 software package. RESULTS: Stathmin expression predicted the response of TPF induction chemotherapy in OSCC patients. OSCC patients with lower Stathmin expression benefited from TPF induction chemotherapy, while OSCC patients with higher Stathmin expression did not benefit from TPF induction chemotherapy. Stathmin expression was an independent predictor of long-term prognosis. CONCLUSIONS: Stathmin is an independent biomarker for predicting the efficacy of TPF induction chemotherapy in OSCC. Subsequent clinical studies based on Stathmin screening will be meaningful for choice of TPF induction chemotherapy in OSCC.

Key words: Oral squamous cell carcinoma, Stathmin, Induction chemotherapy, Prognosis

中图分类号:

R739.8

谈亦然, 赵铜超, 王丽珍, 李江, 琚梧桐, 朱东旺, 张志愿, 钟来平. Stathmin表达与局部晚期口腔鳞癌患者TPF诱导化疗远期疗效的相关性分析[J]. 中国口腔颌面外科杂志, 2021, 19(3): 217-221.

TAN Yi-ran, ZHAO Tong-chao, WANG Li-zhen, LI Jiang, JU Wu-tong, ZHU Dong-wang, ZHANG Zhi-yuan, ZHONG Lai-ping. Stathmin expression correlated with the long-term survival benefit from TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2021, 19(3): 217-221.

参考文献

[1] Zhong LP, Zhang ZY.Reply to K. Devisetty et al[J]. J Clin Oncol, 2013, 31(23): 2972-2973.
[2] Ma HL, Jin SF, Ju WT, et al.Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2017, 36(1): 109-123.
[3] Ju WT, Ma HL, Zhao TC, et al.Stathmin guides personalized therapy in oral squamous cell carcinoma[J]. Cancer Sci, 2020, 111(4): 1303-1313.
[4] Tanaka C, Uzawa K, Shibahara T, et al.Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis[J]. J Dent Res, 2003, 82(8): 607-611.
[5] Khoo E, O'Neill S, Brown E, et al. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases[J]. HPB (Oxford), 2016,18(6): 485-493.
[6] Riba LA, Russell T, Alapati A, et al.Characterizing response to neoadjuvant chemotherapy in invasive lobular breast carcinoma[J]. J Surg Res, 2019, 233: 436-443.
[7] Bossi P, Lo VS, Guzzo M, et al.Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial[J]. Ann Oncol, 2014, 25(2): 462-466.
[8] Cohen EE, Karrison TG, Kocherginsky M, et al.PhaseⅢrandomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer[J]. J Clin Oncol, 2014, 32(25): 2735-2743.
[9] Maghami E, Koyfman SA, Weiss J.Personalizing postoperative treatment of head and neck cancers[J]. Am Soc Clin Oncol Educ Book, 2018, 38: 515-522.
[10] Kim R, Hahn S, Shin J, et al.The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis[J]. Cancer Res Treat, 2016, 48(3): 907-916.

[1]	苏姿尚, 崔文丽, 张梦云, 姚志涛. 口腔鳞状细胞癌患者颈部淋巴结特征与预后的关系[J]. 中国口腔颌面外科杂志, 2023, 21(1): 41-48.
[2]	刘恒, 段晓峰. 铁自噬及相关基因NCOA4、FTH1在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(1): 87-91.
[3]	杨慧丽, 王宇帆, 王锋, 沈月洪, 杨宏宇. NLRP1在头颈部鳞癌中的表达及预后意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 429-436.
[4]	季萍萍, 李莉, 吴奕帆, 侯黎莉. 经皮穴位电刺激防治口腔鳞癌患者诱导化疗后骨髓抑制的效果观察[J]. 中国口腔颌面外科杂志, 2022, 20(5): 455-460.
[5]	许刚, 宋其义, 蒋卫东, 刘景秀. 水通道蛋白3在口腔鳞癌中的表达及临床意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 478-482.
[6]	赵小妹, 夏荣辉, 钟来平, 朱东旺, 张志愿. Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响[J]. 中国口腔颌面外科杂志, 2022, 20(4): 366-370.
[7]	杨宋, 王宁, 赵树超, 李恒勇, 葛胜优, 周凯, 宋凯, 尚伟, 冯元勇. Chemerin在合并2型糖尿病口腔鳞癌患者肿瘤中的表达及临床意义[J]. 中国口腔颌面外科杂志, 2022, 20(4): 390-395.
[8]	张益益, 杨玥怡, 琚梧桐, 钟来平. 局部晚期口腔鳞癌新辅助免疫靶向治疗2例及文献复习[J]. 中国口腔颌面外科杂志, 2022, 20(4): 413-416.
[9]	魏东亮, 李智, 鞠侯雨, 吴云腾, 郭伟, 任国欣. EGFR靶向药物对口腔癌疼痛缓解作用的机制探讨[J]. 中国口腔颌面外科杂志, 2022, 20(3): 219-224.
[10]	杨金刚, 夏荣辉, 朱云, 吴思成, 董亚兵, 杨功鑫, 史俊隆, 崔迎慧, 朱凌, 周晌辉. 98例原发性颌骨内鳞状细胞癌预后影响因素的回顾性分析[J]. 中国口腔颌面外科杂志, 2022, 20(3): 239-243.
[11]	孙大为, 张云, 朱勇. shRNA干扰Rce1基因表达对口腔鳞癌细胞放射敏感性的影响[J]. 中国口腔颌面外科杂志, 2022, 20(2): 123-128.
[12]	努尔曼古丽·牙森, 多力昆·吾甫尔, 白尔娜·吾守尔, 闫广鹏. 血清IL-6、IL-17、TNF-α和IFN-γ水平与60例口腔鳞癌患者临床特征关系探讨[J]. 中国口腔颌面外科杂志, 2022, 20(2): 141-145.
[13]	陈一铭, Ahmed, 季彤, 任振虎. 101例头颈部横纹肌肉瘤临床、病理及预后分析[J]. 中国口腔颌面外科杂志, 2022, 20(2): 146-150.
[14]	瞿楚翔, 孙树洋, 张志愿. 从遗传异质性认识口腔鳞癌的侵袭过程[J]. 中国口腔颌面外科杂志, 2022, 20(2): 193-197.
[15]	王育新, 王志勇, 王永功, 王慧明, 王丽珍, 田皞, 叶金海, 付坤, 阮敏, 孙长伏, 孙国文, 刘法昱, 许碧云, 后军, 刘冰, 刘亮, 陈永锋, 陈占伟, 肖灿, 李思毅, 李志勇, 李勇, 李楠, 张陈平, 张东升, 张胜, 张凯, 杨溪, 何巍, 苏彤, 季彤, 林李嵩, 罗瑞华, 赵志立, 胡勤刚, 唐瞻贵, 徐蔚嘉, 黄志权, 黄晓峰, 梁玉洁, 韩正学, 韩伟, 蒋灿华, 喻建军, 蔡志刚, 廖贵清, 廖圣恺, 蔡惠明, 魏建华. 吲哚菁绿荧光成像技术在口腔鳞癌治疗中的应用：中国专家共识[J]. 中国口腔颌面外科杂志, 2022, 20(1): 1-6.

Stathmin表达与局部晚期口腔鳞癌患者TPF诱导化疗远期疗效的相关性分析

Stathmin expression correlated with the long-term survival benefit from TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价